News ReleasesPrinter friendly version
Protox Therapeutics to Present at Technology and Life Sciences Forum
Wednesday, June 7, 2006 - Vancouver, British Columbia - Protox Therapeutics Inc.
(TSX-V: PRX) announced today that Dr. Fahar Merchant, Protox‘s President and Chief
Executive Officer, will be a featured presenter at the 2006 Fasken Martineau Technology
and Life Sciences Forum to be held June 13, 2006 at the Hyatt Regency Vancouver in British
Columbia.
The 2006 Fasken Martineau Technology and Life Sciences Forum is a full day event in which
public companies from British Columbia's technology and life sciences industries present
their technology and progress to members of the investment community.
Dr. Merchant‘s presentation will take place at 10:00a.m. PST in the Regency A Room.
For more information about the forum, visit the forum website at
www.faskenforum.com or contact Jennifer Despins at Fasken Martineau directly at
604-631-3296 or faskenforum@van.fasken.com.
About Protox Therapeutics:
Protox Therapeutics is a product-focused development-stage company and a leader in
advancing novel, targeted protein toxin therapeutics for treatment of cancer and
other diseases. Through the company’s PORxin™ technology platform,
therapeutic candidates are generated by engineering the naturally occurring protein,
pro-aerolysin. These proteins become potent anti-cancer agents when activated at a
tumor site by specific proteases produced by cancer cells. Once activated, the drug
punches holes in the cancer cells causing the contents to leak out and ultimately,
cell death. Protox is in Phase I clinical trial with the lead compound, PRX302,
for the treatment of localized prostate cancer. PRX302 is also being developed for
treatment of benign prostatic hyperplasia.
For more information, contact:
Elayne Wandler
Director, Investor Relations and Corporate Communications, Protox Therapeutics Inc.
Direct: 604-688-4369
Cell: 778-865-0172
Fax: 604-688-0173
ewandler@protoxtherapeutics.com
| 
